Replies to post #143209 on Amarin Corp Plc (AMRN)

[Hey Jakey]

I think you’re 100% right. This is how they’ll do it.

[xblkbk]

Raf,

I think you are correct. Nice find. Thanks

x BLK BK

[jfmcrr]

Check out AMGN's topline PR, below. No data released whatsoever, except

side effects. Full data released 1.5 months later at ACC. Was no data released because of the embargo (I think YES) or because AMGN wasn't very proud of their results (I think NOT)?

For Amarin, AHA is also 1.5 months away from the topline PR. I think we will see a very similar PR as this:

Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study

Landmark Repatha Cardiovascular Outcomes Study Meets Primary and Key Secondary Endpoint

Detailed Results to be Presented at ACC 66th Annual Scientific Session

And a buncha other stuff less the embargoed details....


What can be deduced for the benefit of AMARIN and CVD patients from the Reduce It version of this?

Vascepa is currently available, it's effect on triglycerides in the MARINE and ANCHOR populations is documented, Safety issues for 5 years use are minimal, the object of the exercise is explicitly detailed in the Reduce It study, there is available RWE from currently prescribing physicians and patients for these populations and off label users, and the news, if V met PE and SE's, is good to superb.

It's not a label, it's not AMARIN promote-able yet, it's not out in a peer reviewed journal for the medical public, but for anybody sitting on ready, it's the racer's red lights on/the christmas tree lit, dump the clutch.

[ggwpq]

Raf, good find. It's logical to assume FOURIER database lock took place on 12/31/2016, a round number date like that in the case of Amarin, 8/31/2018. Database lock to top line in FOURIER took slightly over a month, just like what Dew said. Perhaps Sep 4th, 10th and 17th are unreasonable guess on my part due to my inexperience in all matters regarding CVOTs.